Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III HA-irinotecan study to continue enrollment

May 23, 2012

Phase I/II Xerecept results promising in children with cerebral tumors

May 23, 2012

French researchers present new HSP 90 inhibitors

May 23, 2012

Cellceutix gives update on IND for novel p53 anticancer drug

May 22, 2012

Medivation submits NDA for enzalutamide

May 22, 2012

Phase III MISSION trial misses primary endpoint

May 22, 2012

Daiichi Sankyo and the Japanese National Cancer Center enter anticancer collaboration

May 22, 2012

Peregrine Pharmaceuticals reports data from phase IIb study in NSCLC

May 22, 2012

Kinex out-licenses rights to KX-02 in greater China territory

May 22, 2012

DPT-NX7 induces regressions in squamous cell carcinoma model

May 22, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...